Sage Therapeutics cuts more than 330 jobs after announcing its $795 million acquisition
With its planned purchase of Sage, Supernus will have access to Zurzuvae, the only postpartum depression drug approved by the Food and Drug Administration.
'This acquisition represents a major step in bolstering our future growth,' Supernus CEO Jack Khattar said in a statement.
Advertisement
The deal is expected to close in the third quarter of this year.
The last few years have been rocky for Sage, which was founded in 2010 to research treatments for brain diseases and went public in 2014.
The FDA failed to approve Zurzuvae to treat the more common major depressive disorder in 2023. Sage codeveloped the drug with Biogen, another Cambridge biotech.
In August 2023, Sage
Sage rejected a $469 million acquisition offer from Biogen in January, stating the offer undervalued the company.
Advertisement
Supernus, which has existed in different iterations for three decades, specializes in diseases of the central nervous system. The company has several commercial products for the treatment of Parkinson's disease, attention deficit/hyperactivity disorder, epilepsy and migraines.
Marin Wolf can be reached at
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
9 hours ago
- Business Insider
ATMTA Unveils Zink: A Groundbreaking SVM Layer 1 Blockchain with Zero-Knowledge Identity
Empowering Users with Secure On-Chain Profiles, Seamless Permissions, and a New Era of Decentralized Innovation ATMTA, the innovative development team behind the blockbuster blockchain game Star Atlas, today announced the launch of Zink, a revolutionary Solana Virtual Machine (SVM) Layer 1 blockchain. Designed to redefine digital identity and blockchain interactions, Zink introduces a patent-pending zero-knowledge on-chain profile system, enabling unprecedented security, control, and efficiency for users across decentralized applications. Going live Aug. 13 at 12:00 PM PST, the Zink announcement includes the release of a comprehensive lite paper detailing the protocol's tokenomics and technical architecture. This marks the beginning of an exciting roadmap that culminates in the network's mainnet genesis event in December. Key highlights of the Zink launch include: On-Chain Identity Revolution: At the core of Zink is its zero-knowledge on-chain profile, powered by ATMTA's patent-pending 'player profile' primitive, branded as the zProfile. This innovative account architecture provides global permission settings across connected applications, allowing users to automate transaction approvals—such as in-game actions—without compromising security on core assets. It eliminates the need for manual approvals in high-frequency scenarios while maintaining robust protection, setting a new standard for user-centric blockchain experiences. SVM Base Layer: Built on the high-performance Solana protocol, Zink leverages the Solana Virtual Machine to create a scalable, efficient Layer 1 ecosystem. This foundation enables the spawning of a new decentralized universe, optimized for speed, low costs, and seamless interoperability. ZINK Token: The native utility token of the network, ZINK powers transactions, validator staking, user staking, and consensus mechanisms. It serves as the economic backbone of the Zink ecosystem, incentivizing participation and growth. Following the launch, Zink's roadmap includes: Starting in September, XP tracking will commence, kicking off an airdrop campaign that rewards early adopters and community contributors. XP (experience points) will be earned through a variety of mechanics, including participating in Star Atlas gameplay across the MMO built in UE5, SAGE browser 4X game, Holosim, a fully free-to-play port of SAGE, locking ATLAS and POLIS in the Star Atlas DAO lockers, trading on the Galactic Marketplace, amongst others. The airdrop will run through December, distributing 10% of the total ZINK token supply to eligible participants. In December, the genesis event will officially launch Zink on mainnet, transitioning the protocol to full operational status, with all current and future Star Atlas game logic running on the network. 'Zink represents the amalgamation of years of investment into sophisticated infrastructure necessary to operate fully onchain game systems, and beyond. With Zink, we're forging a new frontier where every individual's digital identity empowers them to shape a decentralized universe, and form a true emotional connection to the network they reside on.' says CEO and Founder Michael Wagner. 'On Zink, your digital persona, your avatar, has meaning, represents status and reputation, and can unlock value in ways not possible with existing blockchains.' Zink represents ATMTA's continued commitment to pushing the boundaries of blockchain technology, building on the success of Star Atlas, which has captivated millions with its immersive metaverse and play-to-earn mechanics. For more information on Zink, including the lite paper, visit About ATMTA, Inc. ATMTA is a pioneering development studio at the intersection of gaming and blockchain technology. Best known for creating Star Atlas, a next-generation multiplayer metaverse game on Solana, ATMTA is dedicated to building secure, scalable, and user-empowered digital ecosystems. Headquartered in Las Vegas, NV, ATMTA continues to innovate in the Web3 space, blending cutting-edge tech with engaging experiences. Zink
Business Insider
a day ago
- Business Insider
Gain Therapeutics price target lowered to $6 from $7 at Roth Capital
Roth Capital lowered the firm's price target on Gain Therapeutics (GANX) to $6 from $7 and keeps a Buy rating on the shares after meeting with its CEO to discuss the company's Phase 1b study evaluating lead candidate GT-02287 in Parkinson's disease. The CSF biomarker data expected in Q4 makes most sense 'to gain preliminary conviction' as it better capitulates pathological changes associated with iPD and GBA1-PD vs. serum biomarker analysis, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Boston Globe
2 days ago
- Boston Globe
Biogen sees potential in combining Alzheimer's and obesity drugs
Advertisement Biogen's looking to the growth of its Alzheimer's drug Leqembi to offset the decline of its multiple sclerosis franchise, which is facing competition from cheaper generic drugs. Biogen's new Alzheimer's drug is already facing competition from Eli Lilly & Co.'s Alzheimer's drug, which was approved in the US last year and has since captured around 30 percent of the market, according to analysts. Other companies are also circling. Novo is carrying out clinical trials to assess whether the main ingredient in diabetes drug Ozempic and weight-loss shot Wegovy might help people with early Alzheimer's disease. Research suggests that the weight-loss drug could slow Alzheimer's progression by impacting inflammation and vascular health. Results of Novo's late-stage trial are expected later this year. Advertisement Viehbacher noted that being overweight is a risk factor for Alzheimer's. He cautioned the Novo study 'is a fairly risky proposition,' adding that 'most of the experts we're talking to are not convinced that it will work.' 'It's logical if you have a weight-loss drug that you can see some benefit, but it's actually pretty hard to move the needle on the cognitive side,' Viehbacher added. Alzheimer's drug development has been riddled with failures, even when drugs looked promising in early studies. Leqembi is a partnership between Cambridge, Massachusetts-based Biogen and Japanese drugmaker Eisai Co. Biogen makes the active ingredient for Leqembi in Switzerland. The company then ships it to North Carolina, where it gets made into a product. President Donald Trump recently put a 39 percent tariff on imports from Switzerland. It's unclear whether this would impact Biogen's drug. Still, Viehbacher said the company has the ability to start producing the substance used to make Leqembi in North Carolina for the US market, while continuing to make it in Switzerland for outside the US. He said the company always intended to use its North Carolina facilities to make Leqembi and the potential move was not a direct response to Trump's tariff threats. Last month, Biogen announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park.
